COVID-19 (SARS-COV-2) structural features, pathophysiology and current drug therapy
1 Department of Pharmaceutical Chemistry,India.Goenka College of Pharmacy, Sikar, Rajasthan-332311, India.
2 Faculty of Pharmacy, Bhupal Noble’s University Udaipur Rajasthan, India.
3 Department of Pharmaceutical Sciences, Madhav University, Pindwara, District - Sirohi, Rajasthan.
4 Shri Balaji College of Pharmacy, Jaipur, Rajasthan, India.
5 School of Pharmacy, Raffles University,Nemrana - 301705, Alwar, Rajasthan, India.
Review
World Journal of Biology Pharmacy and Health Sciences, 2023, 13(01), 162-167.
Article DOI: 10.30574/wjbphs.2023.13.1.0222
Publication history:
Received on 29 November 2022; revised on 06 January 2023; accepted on 09 January 2023
Abstract:
The 2019 coronavirus pandemic disease has spread globally. SARS-CoV-2 species in the first and second time waves and new species of Omicron show symptoms in the third wave of COVID-19 worldwide. The first patients were found in Wuhan, China. Due to COVID-19, the main highly infected countries are the U.S. China, European countries, and also India. The SARS-CoV-2 species are betacoronavirus infections that spread from person to person and another object. The COVID-19 SARS species (RNA virus) is majorly infected in the lungs. Some vaccines and some drugs are provided worldwide, but these vaccines are not proper treatment for COVID-19. These vaccines boost immunity and provide relief from the symptoms of COVID-19, but they are not a proper treatment. Antimalarial drugs, antiviral drugs, monoclonal antibodies, and antibiotics are used in the current treatment to stop mechanisms like fusion entry and replication. Identification of COVID-19 through symptoms and properly identified by RT-PCR Prevention and treatment of COVID-19 disease is a promising new research area for pharma companies to develop novel therapeutic agents' inhibition for COVID-19 pathological targets.
Keywords:
Diagnosis of COVID-19; Pathophysiology; Drug therapy; S protein; Replication
Full text article in PDF:
Copyright information:
Copyright © 2023 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0